{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T15:32:12Z","timestamp":1783179132961,"version":"3.54.6"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T00:00:00Z","timestamp":1704326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T00:00:00Z","timestamp":1704326400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s40123-023-00866-y","type":"journal-article","created":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T05:03:55Z","timestamp":1704344635000},"page":"553-570","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Phase IV Multicenter, Prospective, Open-Label Clinical Trial of Cenegermin (rhNGF) for Stage 1 Neurotrophic Keratopathy (DEFENDO)"],"prefix":"10.1007","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct04485546","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Pedram","family":"Hamrah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Massaro-Giordano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Schanzlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Holland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregg","family":"Berdy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Goisis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgea","family":"Pasedis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavio","family":"Mantelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,4]]},"reference":[{"key":"866_CR1","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.preteyeres.2018.04.003","volume":"66","author":"HS Dua","year":"2018","unstructured":"Dua HS, Said DG, Messmer EM, Rolando M, Benitez-Del-Castillo JM, Hossain PN, et al. Neurotrophic keratopathy. Prog Retin Eye Res. 2018;66:107\u201331.","journal-title":"Prog Retin Eye Res"},{"issue":"2","key":"866_CR2","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/aos.13844","volume":"97","author":"M Labetoulle","year":"2019","unstructured":"Labetoulle M, Baudouin C, Calonge M, Merayo-Lloves J, Boboridis KG, Akova YA, et al. Role of corneal nerves in ocular surface homeostasis and disease. Acta Ophthalmol. 2019;97(2):137\u201345.","journal-title":"Acta Ophthalmol"},{"key":"866_CR3","volume-title":"Corneal reflex","author":"DC Peterson","year":"2022","unstructured":"Peterson DC, Hamel RN. Corneal reflex. Treasure Island: StatPearls Publishing; 2022."},{"issue":"5","key":"866_CR4","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S0014-4835(03)00050-2","volume":"76","author":"LJ M\u00fcller","year":"2003","unstructured":"M\u00fcller LJ, Marfurt CF, Kruse F, Tervo TM. Corneal nerves: structure, contents and function. Exp Eye Res. 2003;76(5):521\u201342.","journal-title":"Exp Eye Res"},{"issue":"4","key":"866_CR5","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1002\/jcp.25623","volume":"232","author":"L Mastropasqua","year":"2017","unstructured":"Mastropasqua L, Massaro-Giordano G, Nubile M, Sacchetti M. Understanding the pathogenesis of neurotrophic keratitis: the role of corneal nerves. J Cell Physiol. 2017;232(4):717\u201324.","journal-title":"J Cell Physiol"},{"issue":"11","key":"866_CR6","doi-asserted-by":"publisher","first-page":"4695","DOI":"10.1167\/iovs.16-21372","volume":"58","author":"G Di","year":"2017","unstructured":"Di G, Qi X, Zhao X, Zhang S, Danielson P, Zhou Q. Corneal epithelium-derived neurotrophic factors promote nerve regeneration. Investig Ophthalmol Vis Sci. 2017;58(11):4695\u2013702.","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"4","key":"866_CR7","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1159\/000354380","volume":"231","author":"F Semeraro","year":"2014","unstructured":"Semeraro F, Forbice E, Romano V, Angi M, Romano MR, Filippelli ME, et al. Neurotrophic keratitis. Ophthalmologica. 2014;231(4):191\u20137.","journal-title":"Ophthalmologica"},{"issue":"16","key":"866_CR8","doi-asserted-by":"publisher","first-page":"12615","DOI":"10.3390\/ijms241612615","volume":"24","author":"K Feinberg","year":"2023","unstructured":"Feinberg K, Tajdaran K, Mirmoeini K, Daeschler SC, Henriquez MA, Stevens KE, et al. The role of sensory innervation in homeostatic and injury-induced corneal epithelial renewal. Int J Mol Sci. 2023;24(16):12615.","journal-title":"Int J Mol Sci"},{"key":"866_CR9","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.2147\/OPTH.S185184","volume":"13","author":"H Sheha","year":"2019","unstructured":"Sheha H, Tighe S, Hashem O, Hayashida Y. Update on cenegermin eye drops in the treatment of neurotrophic keratitis. Clin Ophthalmol. 2019;13:1973\u201380.","journal-title":"Clin Ophthalmol"},{"key":"866_CR10","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.ajo.2020.04.036","volume":"217","author":"L Mastropasqua","year":"2020","unstructured":"Mastropasqua L, Lanzini M, Dua HS, D\u2019Uffizi A, Di Nicola M, Calienno R, et al. In vivo evaluation of corneal nerves and epithelial healing after treatment with recombinant nerve growth factor for neurotrophic keratopathy. Am J Ophthalmol. 2020;217:278\u201386.","journal-title":"Am J Ophthalmol"},{"key":"866_CR11","volume-title":"Current ocular therapy","author":"I Mackie","year":"1995","unstructured":"Mackie I. Neuroparalytic keratitis. In: Fraunfelder F, Roy F, Meyer S, editors. Current ocular therapy. 4th ed. Philadelphia: WB Saunders; 1995.","edition":"4"},{"issue":"6","key":"866_CR12","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1007\/s00417-021-05535-z","volume":"260","author":"M Roth","year":"2022","unstructured":"Roth M, Dierse S, Alder J, Holtmann C, Geerling G. Incidence, prevalence, and outcome of moderate to severe neurotrophic keratopathy in a German tertiary referral center from 2013 to 2017. Graefes Arch Clin Exp Ophthalmol. 2022;260(6):1961\u201373.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"2","key":"866_CR13","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.jtos.2019.11.008","volume":"18","author":"S Saad","year":"2020","unstructured":"Saad S, Abdelmassih Y, Saad R, Guindolet D, Khoury SE, Doan S, et al. Neurotrophic keratitis: frequency, etiologies, clinical management and outcomes. Ocul Surf. 2020;18(2):231\u20136.","journal-title":"Ocul Surf"},{"issue":"8","key":"866_CR14","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1038\/sj.eye.6700616","volume":"17","author":"S Bonini","year":"2003","unstructured":"Bonini S, Rama P, Olzi D, Lambiase A. Neurotrophic keratitis. Eye (Lond). 2003;17(8):989\u201395.","journal-title":"Eye (Lond)"},{"issue":"1","key":"866_CR15","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1186\/s12886-021-02092-1","volume":"21","author":"R Dana","year":"2021","unstructured":"Dana R, Farid M, Gupta PK, Hamrah P, Karpecki P, McCabe CM, et al. Expert consensus on the identification, diagnosis, and treatment of neurotrophic keratopathy. BMC Ophthalmol. 2021;21(1):327.","journal-title":"BMC Ophthalmol"},{"key":"866_CR16","first-page":"571","volume":"8","author":"M Sacchetti","year":"2014","unstructured":"Sacchetti M, Lambiase A. Diagnosis and management of neurotrophic keratitis. Clin Ophthalmol. 2014;8:571\u20139.","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"866_CR17","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1080\/07853890.2022.2045035","volume":"54","author":"E NaPier","year":"2022","unstructured":"NaPier E, Camacho M, McDevitt TF, Sweeney AR. Neurotrophic keratopathy: current challenges and future prospects. Ann Med. 2022;54(1):666\u201373.","journal-title":"Ann Med"},{"issue":"5","key":"866_CR18","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1001\/archopht.119.5.659","volume":"119","author":"E Letko","year":"2001","unstructured":"Letko E. Amniotic membrane inlay and overlay grafting for corneal epithelial defects and stromal ulcers. Arch Ophthalmol. 2001;119(5):659.","journal-title":"Arch Ophthalmol"},{"key":"866_CR19","unstructured":"Oxervate [prescribing information]. Boston: Domp\u00e9; 2019."},{"key":"866_CR20","unstructured":"US Food and Drug Administration. FDA approves first drug for neurotrophic keratitis, a rare eye disease [news release]. 2018. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-drug-neurotrophic-keratitis-rare-eye-disease. Accessed 5 Oct 2023 (Published August 22, 2018)"},{"issue":"1","key":"866_CR21","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ophtha.2019.08.020","volume":"127","author":"SC Pflugfelder","year":"2020","unstructured":"Pflugfelder SC, Massaro-Giordano M, Perez VL, Hamrah P, Deng SX, Espandar L, et al. Topical recombinant human nerve growth factor (cenegermin) for neurotrophic keratopathy: a multicenter randomized vehicle-controlled pivotal trial. Ophthalmology. 2020;127(1):14\u201326.","journal-title":"Ophthalmology"},{"issue":"9","key":"866_CR22","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1016\/j.ophtha.2018.02.022","volume":"125","author":"S Bonini","year":"2018","unstructured":"Bonini S, Lambiase A, Rama P, Sinigaglia F, Allegretti M, Chao W, et al. Phase II randomized, double-masked, vehicle-controlled trial of recombinant human nerve growth factor for neurotrophic keratitis. Ophthalmology. 2018;125(9):1332\u201343.","journal-title":"Ophthalmology"},{"key":"866_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2022.101649","volume":"27","author":"AT Epitropoulos","year":"2022","unstructured":"Epitropoulos AT, Weiss JL. Topical human recombinant nerve growth factor for stage 1 neurotrophic keratitis: retrospective case series of cenegermin treatment. Am J Ophthalmol Case Rep. 2022;27: 101649.","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"12","key":"866_CR24","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1016\/j.ophtha.2022.08.014","volume":"129","author":"LY Saricay","year":"2022","unstructured":"Saricay LY, Bayraktutar BN, Lilley J, Mah FS, Massaro-Giordano M, Hamrah P. Efficacy of recombinant human nerve growth factor in stage 1 neurotrophic keratopathy. Ophthalmology. 2022;129(12):1448\u201350.","journal-title":"Ophthalmology"},{"key":"866_CR25","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/1477-7525-9-111","volume":"9","author":"L Abetz","year":"2011","unstructured":"Abetz L, Rajagopalan K, Mertzanis P, Begley C, Barnes R, Chalmers R. Development and validation of the impact of dry eye on everyday life (IDEEL) questionnaire, a patient-reported outcomes (PRO) measure for the assessment of the burden of dry eye on patients. Health Qual Life Outcomes. 2011;9:111.","journal-title":"Health Qual Life Outcomes"},{"issue":"9","key":"866_CR26","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1097\/00006324-199109000-00004","volume":"68","author":"NA Brennan","year":"1991","unstructured":"Brennan NA, Bruce AS. Esthesiometry as an indicator of corneal health. Optom Vis Sci. 1991;68(9):699\u2013702.","journal-title":"Optom Vis Sci"},{"issue":"1","key":"866_CR27","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13023-022-02237-5","volume":"17","author":"E Pedrotti","year":"2022","unstructured":"Pedrotti E, Bonacci E, Chierego C, De Gregorio A, Cozzini T, Brighenti T, et al. Eight months follow-up of corneal nerves and sensitivity after treatment with cenegermin for neurotrophic keratopathy. Orphanet J Rare Dis. 2022;17(1):63.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"866_CR28","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1038\/s41598-022-05229-4","volume":"12","author":"D Pieragostino","year":"2022","unstructured":"Pieragostino D, Lanzini M, Cicalini I, Cufaro MC, Damiani V, Mastropasqua L, et al. Tear proteomics reveals the molecular basis of the efficacy of human recombinant nerve growth factor treatment for neurotrophic keratopathy. Sci Rep. 2022;12(1):1229.","journal-title":"Sci Rep"},{"issue":"1","key":"866_CR29","doi-asserted-by":"publisher","first-page":"60","DOI":"10.18240\/ijo.2023.01.09","volume":"16","author":"M Hao","year":"2023","unstructured":"Hao M, Cheng Y, Wu J, Cheng Y, Wang J. Clinical observation of recombinant human nerve growth factor in the treatment of neurotrophic keratitis. Int J Ophthalmol. 2023;16(1):60\u20136.","journal-title":"Int J Ophthalmol"},{"key":"866_CR30","doi-asserted-by":"publisher","first-page":"1210179","DOI":"10.3389\/fnins.2023.1210179","volume":"17","author":"A Balbuena-Pareja","year":"2023","unstructured":"Balbuena-Pareja A, Bogen CS, Cox SM, Hamrah P. Effect of recombinant human nerve growth factor treatment on corneal nerve regeneration in patients with neurotrophic keratopathy. Front Neurosci. 2023;17:1210179.","journal-title":"Front Neurosci"},{"issue":"8","key":"866_CR31","doi-asserted-by":"publisher","first-page":"3629","DOI":"10.1167\/iovs.08-3225","volume":"50","author":"IJ Su\u00f1er","year":"2009","unstructured":"Su\u00f1er IJ, Kokame GT, Yu E, Ward J, Dolan C, Bressler NM. Responsiveness of NEI VFQ-25 to changes in visual acuity in neovascular AMD: validation studies from two phase 3 clinical trials. Invest Ophthalmol Vis Sci. 2009;50(8):3629\u201335.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"866_CR32","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.jtos.2020.09.007","volume":"19","author":"RE Ruiz-Lozano","year":"2021","unstructured":"Ruiz-Lozano RE, Hernandez-Camarena JC, Loya-Garcia D, Merayo-Lloves J, Rodriguez-Garcia A. The molecular basis of neurotrophic keratopathy: diagnostic and therapeutic implications. A review Ocul Surf. 2021;19:224\u201340.","journal-title":"A review. Ocul Surf"},{"key":"866_CR33","volume-title":"Translational pain research: from mouse to man","author":"MP Jankowski","year":"2010","unstructured":"Jankowski MP, Koerber HR. Neurotrophic factors and nociceptor sensitization. In: Kruger L, Light AR, editors. Translational pain research: from mouse to man. Boca Raton: CRC Press\/Taylor & Francis; 2010."},{"issue":"11","key":"866_CR34","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.ophtha.2022.06.019","volume":"129","author":"Y Bian","year":"2022","unstructured":"Bian Y, Ma KK, Hall NE, Elze T, Lorch A, Miller JW, et al. Neurotrophic keratopathy in the United States: an Intelligent Research in Sight Registry analysis. Ophthalmology. 2022;129(11):1255\u201362.","journal-title":"Ophthalmology"},{"issue":"8","key":"866_CR35","first-page":"2623","volume":"260","author":"S Roumeau","year":"2022","unstructured":"Roumeau S, Dutheil F, Sapin V, Baker JS, Watson SL, Pereira B, et al. Efficacy of treatments for neurotrophic keratopathy: a systematic review and meta-analysis. Graefes Arch Clin Exp Ophthalmol. 2022;260(8):2623\u201337.","journal-title":"Graefes Arch Clin Exp Ophthalmol"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-023-00866-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-023-00866-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-023-00866-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,13]],"date-time":"2024-01-13T15:10:39Z","timestamp":1705158639000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-023-00866-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,4]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["866"],"URL":"https:\/\/doi.org\/10.1007\/s40123-023-00866-y","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,4]]},"assertion":[{"value":"8 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Pedram Hamrah has received financial support from CooperVision, Domp\u00e9 farmaceutici S.p.A., Novartis, Ocular Therapeutix, and OKYO Pharma and has served as a contractor\/consultant for Domp\u00e9 farmaceutici S.p.A., Kala Pharmaceuticals, Novaliq, Novartis, OKYO Pharma, and Oyster Point Pharma. Mina Massaro-Giordano has served as a consultant for Claris Bio, Domp\u00e9 farmaceutici S.p.A., Kala Pharmaceuticals, Lynthera, Oyster Point, and Tarsus. David Schanzlin has no conflicts of interest to disclose. Edward Holland has served as a consultant for Alcon. Gregg Berdy has served as a researcher for Aerie (now Alcon), Alcon, Allakos, Allergan\/AbbVie, Bausch\u2009+\u2009Lomb, ClarisBio, Domp\u00e9, Kala, Novaliq (now Bausch\u2009+\u2009Lomb), Tarsus, Tear Care, Tear Film Innovations, and Tear Solutions; has consulted for Aerie (now Alcon), Alcon, Allergan\/AbbVie, Bausch\u2009+\u2009Lomb, Domp\u00e9, Novartis, Sun, Tarsus, Tear Care, and Tear Solutions; and has lectured for Aerie (now Alcon), Alcon, Allergan\/AbbVie, Bausch\u2009+\u2009Lomb, Domp\u00e9, Novartis, Sun, Tarsus, and Tear Care. Giovanni Goisis was an employee of Domp\u00e9 farmaceutici S.p.A. at the time of this study but is no longer affiliated with the company. Georgea Pasedis and Flavio Mantelli are employees of Domp\u00e9 farmaceutici S.p.A.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Institutional review board approval was obtained for the study protocol, protocol amendments, informed consent forms, and any other relevant study-related documents at each center (Sterling IRB, 8203-DJSchanzlin, 8203-EJHolland, 8203-GJBerdy, 8203-MMassaroGiordano; and WCG-WIRB, 20202809). The study complied with the Declaration of Helsinki, relevant parts of the Code of Federal Regulations Title 21, and good clinical practice and good laboratory practice guidelines. Written informed consent was obtained from all patients before study initiation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}